Peninsula Cancer Center (PENC) was established by Binzhou Medical University, Yantai Affiliated Hospital of Binzhou Medical University, Harvard University Cancer Center, New York Sloan Cancer Center, Cambridge University, and other international cancer centers. It is a school-level research institution affiliated to Binzhou Medical University.
At present, the Peninsula Cancer Center has a laboratory area of more than 2,000 square meters. It focuses on establishing a comprehensive experimental platform for multi-disciplinary and multi-level tumor basic research and translational application, including mass spectrometry testing platform, anti-tumor drug R&D platform and digital pathology platform, with a total value of RMB 80 million yuan. The Translational Medicine Protein Analysis Center of Binzhou Medical University, Disease Animal Model Center, Tumor Diagnosis and Treatment Technology Center, and Monoclonal Antibody Center (under preparation) will be constructed on the basis of PENC and available resources. The platform has reached the domestic leading level, and some research have reached international advanced level. It has become a strong cornerstone for the Binzhou Medical University to undertake major national scientific research tasks and carry out scientific research work facing the international frontier.
PENC has a scientific research team specializing in basic cancer research and applied basic research. It has not only a number of academic leaders with international academic influence, but also a young academic backbone with strong pioneering and innovative capabilities, and strong overall research strength and international academic competitiveness.
Many professors at Peninsula Cancer Center currently serve in academic institutions at home and abroad, serving as editorial board members, associate editors, and editor-in-chiefs of internationally representative journals including JBC.
The core team of PENC is composed of principal investigators (PI) who are engaged in molecular biology, pharmacology, medicinal chemistry and clinic of tumors. It aims to integrate the superior strength and superior resources of Binzhou Medical University and its affiliated hospitals, focusing on common malignant tumors in China, and to build a leading domestic and internationally recognized cancer medical research and medical innovation base through the close integration of basic-clinical-transformation.
PENC makes full use of abundant clinical cases, and leverages the advantages of multidisciplinary collaboration in immunology, genetics, molecular biology, pathology, and clinical medicine to carry out tumor pathogenesis, early diagnosis and treatment of high-risk populations, and clinical diagnosis and treatment target discovery and drug research and development, making important progress in the pathogenesis and translational research of lung cancer and other tumors, including:
1. Establishing the apparent post-translational modification profile of tumor proteins;
2. R & D of accurate targeting anti-cancer drugs to tumor immune nodes;
3. Pioneering circulating tumor cell detection and dialysis.
